Speaker Profile
Ph.D., CEO, Founder, NeoSplice Tx
Biography
Evgeny Kiner is the founder of NeoSplice Therapeutics, an AI-driven platform company unlocking disease-specific therapeutic targets that are inaccessible to traditional genomics. He was trained in RNA biology at Massachusetts Institute of Technology under Phillip Sharp, and later in systems immunology at Harvard University with Diane Mathis and Christophe Benoist, where he helped bring single-cell RNA sequencing into large-scale immune profiling efforts as part of the Immgen consortium. He is the author of a highly cited Nature Immunology study that reshaped understanding of CD4 T-cell states. Prior to Neo Splice, he was a founding scientist at Immunai, where he helped build AI-driven platforms for biological discovery. Evgeny is passionate about expanding the druggable target space and accelerating the path from data to medicines using AI.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures & Gad Getz, Broad Institute
PMWC Award Ceremony
• David Baker, University of Washington (Nobel Laureate, Luminary)
Featured Speakers
• David Baker, University of Washington
• Jack Dent, Chai Discovery
• Dimitri Yatsenko, DataJoint
• Evgeny Kiner, Neosplice Therapeutics
• Alex Morgan, Khosla Ventures
• Gad Getz, Broad Institute
Causal Targets, Not Just Better Molecules
Using AI and human biology to improve target selection before chemistry begins.
Data Is the Moat
What proprietary, longitudinal, and perturbational data really confer advantage.
From Prediction to Patient
Patient stratification, smarter trials, and the handoff from model to clinic.
Designed Biology Meets Drug Development
AI-designed proteins, developability, and what survives contact with reality.
The Target Discovery Bottleneck
Why splicing and other underused biology may expand what is druggable.
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
